NCT05765110 SPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease
| NCT ID | NCT05765110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-01-03 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-01-03 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
With this study, the investigators want to investigate whether computerized speech analysis can be used to reliably and objectively detect motor, emotional, and cognitive fluctuations in Parkinson's disease patients.
Eligibility Criteria
Patients with Parkinson's Disease Inclusion Criteria: * Written informed consent * Idiopathic PD according to the Movement Disorders Society Criteria; * Age of participants \> 30 and ≤ 75 years; * Treatment with or without bilateral deep brain stimulation in the subthalamic nucleus; * Fluent in German or French Exclusion Criteria: * Dysarthria caused in addition by a condition other than PD (e.g. stroke, myasthenia); * Clinical diagnosis of aphasia; * Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.). * Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points); * Depression with acute suicidal ideation Healthy Controls Inclusion Criteria: * Written informed consent * Adults from 50-70 years old; * Fluent in German or French Exclusion Criteria: * Diagnosis of Parkinson's disease; * Cognitive impairment (Montreal Cognitive Assessment (MoCa) \< 24/30 points); * Suffering from brain disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.); * Clinical diagnosis of aphasia, dysarthria, and stuttering; * Suffering from or diagnosed with psychiatric illnesses according to DSM-V criteria
Contact & Investigator
Paul Krack, Prof.
PRINCIPAL INVESTIGATOR
Insel Gruppe AG, University Hospital Bern
Frequently Asked Questions
Who can join the NCT05765110 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 75 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05765110 currently recruiting?
Yes, NCT05765110 is actively recruiting participants. Contact the research team at paul.krack@insel.ch for enrollment information.
Where is the NCT05765110 trial being conducted?
This trial is being conducted at Prague, Czechia, Bern, Switzerland.
Who is sponsoring the NCT05765110 clinical trial?
NCT05765110 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Paul Krack, Prof. at Insel Gruppe AG, University Hospital Bern. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.